Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy

02 May 2023

• By Ayisha Sharma

Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.

ENPP1 Deficiency Can Cause Arterial Calcification And Eventual Death • Source: Shutterstock

Inozyme Pharma Inc. is on a mission to treat two ultra-rare and often fatal mineralization disorders that currently have no approved options with its lead enzyme therapy asset that has the potential to be a ‘pipeline in a product.’

The Boston, MA-headquartered had a strong start with a $50m seed funding in January 2017 followed by a second private...